Year All2024202320222021202020192018201720162015201420132012201120102007 11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end - - Data from Phase 1 trial Read More 10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial Read More 09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update -- Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT-101 to expand enrollment to pediatric patients and focus exclusively on patients with MLL-r and NPM1 mutant acute leukemias -- -- Recommended Phase 2 dose for AUGMENT-101 anticipated by year end; full Phase 1 data Read More 08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate Read More 07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020 WALTHAM, Mass. , July 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial Read More 07.07.20 Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer - Richard P. Shea to Retire as Chief Financial Officer - WALTHAM, Mass. , July 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the Read More 05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer WALTHAM, Mass. , May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that Read More 05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected this quarter; potential NDA filing later this year - - Preliminary Phase 1 results from AUGME-T-101 trial of menin inhibitor SNDX-5613 represent first clinical evidence that inhibition of the menin-MLL1 Read More 04.30.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today the pricing of an underwritten public offering Read More 04.30.20 Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020 WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX ), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2020 financial Read More
11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end - - Data from Phase 1 trial Read More
10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial Read More
09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update -- Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT-101 to expand enrollment to pediatric patients and focus exclusively on patients with MLL-r and NPM1 mutant acute leukemias -- -- Recommended Phase 2 dose for AUGMENT-101 anticipated by year end; full Phase 1 data Read More
08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate Read More
07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020 WALTHAM, Mass. , July 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial Read More
07.07.20 Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer - Richard P. Shea to Retire as Chief Financial Officer - WALTHAM, Mass. , July 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the Read More
05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer WALTHAM, Mass. , May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that Read More
05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected this quarter; potential NDA filing later this year - - Preliminary Phase 1 results from AUGME-T-101 trial of menin inhibitor SNDX-5613 represent first clinical evidence that inhibition of the menin-MLL1 Read More
04.30.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today the pricing of an underwritten public offering Read More
04.30.20 Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020 WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX ), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2020 financial Read More